Slide 1: Conference on FY2026.12 Q1 Financial Results
Conference on FY2026.12 Q1 Financial Results 24 April 2026 CHUGAI PHARMACEUTICAL CO., LTD.
Slide 2: Important Reminder
Important Reminder Forward-Looking Statements This presentation may include forward-looking statements pertaining to the business and prospects of Chugai Pharmaceutical Co., Ltd. (the “Company”). These statements reflect the Company’s current analysis of existing information and trends. Actual resul
Slide 3: Agenda
Agenda 01 FY2026 Q1 Overview President & CEO Dr. Osamu Okuda FY2026 Q1 Overview of Development Executive Vice President, Head of Project & Pipeline 02 Lifecycle Management Unit Tsukasa Kusano FY2026 Q1 Consolidated Financial 03 Director, Executive Vice President & CFO Overview (Core) Iwaaki Taniguch
Slide 4: FY2026 Q1 Overview
FY2026 Q1 Overview President & CEO Dr. Osamu Okuda
Slide 5: Financial Overview
FY2026 Q1 Overview Financial Overview Achieved increased revenue and profit, driven by steady domestic and overseas sales Growth led by Hemlibra exports, as well as NEMLUVIO* exports to third parties and the associated royalty income 2025 2026 2026 Core Growth (billions of JPY) Jan - Mar Jan - M
Slide 6: Topline Overview
FY2026 Q1 Overview Topline Overview Domestic sales 【Billions of JPY】 Overseas sales Increased YoY. Mainstay products +23.4 (Vabysmo, Hemlibra, Polivy, Phesgo) and new product Export unit Sales volume price etc.** -1.5 (Lunsumio) performed favorably, +2.9 despite the effects of the NHI drug Domesti
Slide 7: Main Progress in Q1 (1/2)
FY2026 Q1 Overview Main Progress in Q1 (1/2) Advancing the Development Pipeline NXT007: Two Phase 3 studies (ZEBRHA 1/2 studies*1) expected to start in Q2, targeting filing in 2028 emugrobart: Discontinued development for SMA*2 and FSHD.*3 Phase 2 study for obesity will continue as planned, with
Slide 8: Main Progress in Q1 (2/2)
FY2026 Q1 Overview Main Progress in Q1 (2/2) Multiple New Product Launches and Indication Expansions Elevidys: Launched as Japan's first gene therapy product for DMD*1 Lunsumio and Polivy combination: Approved for the first time in the world in Japan for r/r LBCL*2 Lunsumio: Launched subcutane
Slide 9: Composition of Board of Directors
FY2026 Q1 Overview Composition of Board of Directors (as of April 1, 2026) Ensuring the appropriate diversity and scale of the Board as a whole, including the necessary expertise, competencies, gender, internationality, work experience and age, to enable prompt and decisive management decisions wi
Slide 10: FY2026 Q1 Overview of Development Pipeline
FY2026 Q1 Overview of Development Pipeline Executive Vice President, Head of Project & Lifecycle Management Unit Tsukasa Kusano
Slide 11: Q1 Topics (1/2)
FY2026 Q1 Overview of Development Pipeline Q1 Topics (1/2) Launched Elevidys Duchenne muscular dystrophy * February 2026 Enspryng Addition of dosage form (auto-injector) March 2026 Foundayo** Adults with obesity, or overweight with weight-related medical problems April 2026 (U.S.) Rituxan Autoimmune
Slide 12: Q1 Topics (2/2)
FY2026 Q1 Overview of Development Pipeline Q1 Topics (2/2) Foundayo* P3 ACHIEVE-4 study (Type 2 diabetes): PE was met April 2026 Readout giredestrant P3 persevERA study (Estrogen receptor (ER)-positive breast cancer): PE was not met March 2026 EAHAD: P1/2 NXTAGE study Part C (Hemophilia A, direct sw
Slide 13: 2026: Key R&D Milestones
FY2026 Q1 Overview of Development Pipeline 2026: Key R&D Milestones Underlined and bolded: Changes since January 29, 2026 Product Indication / Study name Progress ALK fusion / rearrangement gene-positive unresectable advanced Alecensa Projects to be or recurrent solid tumors Approved Lunsumio + Poli
Slide 14: NXT007: Switch from Emicizumab without Washout Period
FY2026 Q1 Overview of Development Pipeline NXT007：Switch from Emicizumab without Washout Period First data in people with hemophilia A with or without factor VIII inhibitors when switching from emicizumab to NXT007 starting with a loading dose without a washout period Similar to Part B in emiciz
Slide 15: Enspryng (MOGAD): METEOROID study
FY2026 Q1 Overview of Development Pipeline Enspryng (MOGAD): Phase 3 METEOROID study (2026 American Academy of Neurology) Global Phase III study for MOGAD (METEOROID) met its primary endpoint (time to first relapse of MOGAD), with a 68% reduction in the risk of new MOGAD relapse compared with plac
Slide 16: Projected Submissions
FY2026 Q1 Overview of Development Pipeline Projected Submissions (Phase 2 & Later Programs and Products) aHUS: atypical hemolytic uremic syndrome NF2: Neurofibromatosis type 2 Filed BC: breast cancer DMD: Duchenne muscular dystrophy NSCLC: non-small cell lung cancer r/r DLBCL: relapsed or refractory
Slide 17: Advances in Major Chugai Originated Projects Out-Licensed (1/2)
FY2026 Q1 Overview of Development Pipeline Advances in Major Chugai Originated Projects Out-Licensed to 3rd Parties (1/2) ★: Changes since January 29, 2026 Generic name/ Mode of Granted rights to Development Licensee Stage Indication Progress Action licensee code US: Obtained approval in May 2025
Slide 18: Advances in Major Chugai Originated Projects Out-Licensed (2/2)
FY2026 Q1 Overview of Development Pipeline Advances in Major Chugai Originated Projects Out-Licensed to 3rd Parties (2/2) Generic name/ Granted Mode of Development Licensee rights to Stage Indication Progress Action code licensee Obtained US FDA approval as an obesity treatment in Q2 2026 ★ US: La
Slide 19: Enspryng: MOGAD
FY2026 Q1 Overview of Development Pipeline Enspryng: Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD) Blockade of IL-6 signalling may lead to reduced pathogenic autoantibody production and anti-inflammatory effects. Conceptual 4) Diagram 1) MOGAD is a demyelinating disorde
Slide 20: FY2026 Q1 Consolidated Financial Overview (Core)
FY2026 Q1 Consolidated Financial Overview(Core) Director, Executive Vice President & CFO Iwaaki Taniguchi
Slide 21: P/L Jan–Mar Year on Year
FY2026 Q1 Consolidated Financial Overview (Core) P/L Jan – Mar (Year on Year) Domestic sales STRICTLY CONFIDENTIAL Increase due to growth of mainstay products and new products, despite decrease due to the NHI drug price (Billions of JPY) 2025 2026 Growth revisions and the market penetration of gen
Slide 22: Sales Jan–Mar Year on Year
FY2026 Q1 Consolidated Financial Overview (Core) Sales Jan – Mar (Year on Year) STRICTLY CONFIDENTIAL Sales by Disease Area, Sales by Product, Year on Year Year on Year (Billions of JPY) ( ) Actual sales in FY2026 %: Year-on-year percentage change *Included in Others in the Specialty area **Patient
Slide 23: Operating Profit Jan–Mar Year on Year
FY2026 Q1 Consolidated Financial Overview (Core) Operating Profit Jan – Mar(Year on Year) Increase in STRICTLY CONFIDENTIAL various costs (Billions of JPY) Overseas sales and increase in +23.4 Increase in other cost of sales operating +1.5 -4.8 income Increase in +9.9 other revenue -4.7 Domestic sal
Slide 24: Structure of Costs and Profit by Quarter
FY2026 Q1 Consolidated Financial Overview (Core) Structure of Costs and Profit by Quarter STRICTLY CONFIDENTIAL (Billions of JPY) Year on Year (vs. 2025 Q1) % of Revenue (% of sales for See the slide “P/L Jan – Mar (Year on Year)” cost of sales) Operating Profit +23.8, +17.1% Cost of sales R&D exp
Slide 25: Structure of Revenue by Quarter
FY2026 Q1 Consolidated Financial Overview (Core) Structure of Revenue by Quarter STRICTLY CONFIDENTIAL (Billions of JPY) Year on Year (vs. 2025 Q1) % of Revenue See the slide “P/L Jan – Mar (Year on Year)” Other revenue Overseas sales Quarter on Quarter (vs. 2025 Q4) Domestic sales: decrease fol
Slide 26: P/L Jan–Mar vs. Forecast
FY2026 Q1 Consolidated Financial Overview (Core) P/L Jan – Mar (vs. Forecast) STRICTLY CONFIDENTIAL Actual Forecast 2025 Domestic sales (Billions of JPY) 2026 2026 Mostly in line with the forecast Progress Progress* Jan - Mar Jan - Dec Overseas sales Revenue 321.7 1,345.0 23.9% 22.9% Mostly in l
Slide 27: Sales Jan–Mar vs. Forecast
FY2026 Q1 Consolidated Financial Overview (Core) Sales Jan – Mar (vs. Forecast) STRICTLY CONFIDENTIAL Actual Original Forecast 2025 Actual Original Forecast 2025 (Billions of JPY) 2026 2026 (Billions of JPY) 2026 2026 Progress Progress * Progress Progress * Jan - Mar Jan - Dec Jan - Mar Jan - Dec Sa
Slide 28: Impact from Foreign Exchange Jan–Mar
FY2026 Q1 Consolidated Financial Overview (Core) Impact from Foreign Exchange Jan – Mar STRICTLY CONFIDENTIAL vs.2025 vs.2026 2025 2026 2026 2026 2026 Actual rate Forecast rate Exchange Actual Forecast Actual rate** Market Forecast (Billions of JPY) Rate rate** rate Jan –Mar average rate Jan - Mar J
Slide 29: Financial Position vs. 2025 Year End
FY2026 Q1 Consolidated Financial Overview (Core) Financial Position (vs. 2025 Year End) STRICTLY CONFIDENTIAL (Billions of JPY) Total assets 2,468.6 -203.5 2,265.1 Decrease in net working capital Total liabilities -442.9 +85.5 -357.4 Decrease mainly in other accounts receivable 2,025.7 Total net a
Slide 30: Net Cash vs. 2025 Year End
FY2026 Q1 Consolidated Financial Overview (Core) Net Cash (vs. 2025 Year End) STRICTLY CONFIDENTIAL (Billions of JPY) ■ Operating profit after adjustment * +169.6 Total investment Operating profit * +158.8 Income tax payable, etc. Depreciation, amortization and impairment * +8.8 +56.7 -23.0 Dividend
Slide 31: P/L Jan–Mar Non-core Adjustment
FY2026 Q1 Consolidated Financial Overview (Core) P/L Jan – Mar (Non-core adjustment) STRICTLY CONFIDENTIAL Non-core items Non-core items IFRS Core (Billions of JPY) Intangible results Others results Factors affected operating profit assets Revenue 321.7 321.7 Intangible assets Sales 291.6 291.6 Am
Slide 32: Current Status / Plan for Major Investments
FY2026 Q1 Consolidated Financial Overview (Core) Current Status / Plan for Major Investments STRICTLY CONFIDENTIAL Planned investment ～2025 2026 2027 2028 2029 2030 2031～ Period* Investment Total amount Unit to-date Utsunomiya plant UT3: Manufacture bio drug substance for middle to later- stage clin
Slide 33: Contacts
Contacts Corporate Communications Dept. For Media: Media Relations Group Tel： +81 (0)3-3273-0881 E-mail： pr@chugai-pharm.co.jp Person in Naoki Kouzai, Hitomi Shiobara, Atsuki Hirano, Ikue Miyazawa, charge： Kaho Izumi For Investors: Investor Relations Group Tel： +81 (0)3-3273-0554 E-mail： ir@chugai-p
Slide 34: INNOVATION BEYOND IMAGINATION
INNOVATION BEYOND IMAGINATION [= CHUGAI PHARMACEUTICAL A member of the Roche group